An interventional study of PAXMAN Orbis Scalp Cooler and Control No treatment in Breast Cancer and Alopecia, sponsored by Julie Nangia. Status unknown at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Julie Nangia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
Cooling the scalp during chemotherapy may help reduce the chances of losing hair during treatment. The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device may stop patients who are undergoing chemotherapy from losing their hair.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's enrollment of 236 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Julie Nangia is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scalp Cooling
Device: PAXMAN Orbis Scalp Cooler
Control
Other: Control No treatment
Treatment with Orbis scalp cooling cap
No treatment to prevent hair loss
Also known as: No intervention
Hair Preservation
The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade \<2, and will be assessed by a healthcare professional who is blinded to study treatment.
Time frame: 4 to 8 Months
Time to First Recurrence and Overall Survival
A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation
Time frame: 5 years
Improved Quality of Life
Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.
Time frame: 4 to 8 Months
| Milestone | PAXMAN Orbis Scalp Cooler | Control No Treatment |
|---|---|---|
| Started | 157 | 79 |
| Completed | 122 | 51 |
| Not completed | 35 | 28 |
| Withdrew: Withdrawal by subject | 31 | 25 |
| Withdrew: Alternative treatment | 1 | 1 |
| Withdrew: Found not eligible | 3 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Progression disease | 0 | 1 |
The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade \<2, and will be assessed by a healthcare professional who is blinded to study treatment.
| Participants | Scalp Cooling | Non-cooling |
|---|---|---|
| success | 69 | 0 |
| failure | 61 | 54 |
A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation
Results for this outcome have not been posted.
Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.
Results for this outcome have not been posted.
Collected over Adverse events experienced by subjects were collected from initiation of study device, throughout the study for up to 8 cycle of device use, and within 30 days of the last use of study device. Adverse events through 30 days after study completion were collected.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Scalp Cooling | 0/137 (0%) | 0/137 (0%) | 39/137 (28.5%) |
| Non-cooling | — | — | — |
| Event | Scalp Cooling | Non-cooling |
|---|---|---|
| headacheNervous system disorders | 27/137 | — |
| nauseaGastrointestinal disorders | 7/137 | — |
| dizzinessNervous system disorders | 6/137 | — |
| scalp painSkin and subcutaneous tissue disorders | 6/137 | — |
| Dry skinSkin and subcutaneous tissue disorders | 3/137 | — |
| PruritusSkin and subcutaneous tissue disorders | 2/137 | — |
| Ear painEar and labyrinth disorders | 1/137 | — |
| chillsGeneral disorders | 1/137 | — |
| painGeneral disorders | 1/137 | — |
| paresthesiaNervous system disorders | 1/137 | — |
| Age, Continuous(years) | Scalp Cooling | Non-cooling | Total |
|---|---|---|---|
| Mean | 50.4 ± 10.1 | 50.6 ± 10.6 | 50.4 ± 10.3 |
| Sex: Female, Male(Participants) | Scalp Cooling | Non-cooling | Total |
|---|---|---|---|
| Female | 157 | 79 | 236 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Scalp Cooling | Non-cooling | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 12 | 37 |
| Not Hispanic or Latino | 130 | 66 | 196 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Scalp Cooling | Non-cooling | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 5 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 19 | 10 | 29 |
| White | 130 | 62 | 192 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Scalp Cooling | Non-cooling | Total |
|---|---|---|---|
| United States | 157 | 79 | 236 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Patients are aware of whether or not they are using the cooling device and can tell if they have hair loss.
Supporting information: Informed consent form
Time frame: At completion of their participation.
Access criteria: Patients know if they are wearing the device or not.
Ran from May 2014 to primary completion in Feb 2017, 32 months.
Results were first posted in Oct 2018, 1 year 8 months after primary completion.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 32 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Julie Nangia